Eyevensys appoints Dr. Patricia Zilliox, an Experienced Ophthalmology Clinical Development Leader, to Board of Directors
Lead product, EYS606 for uveitis, to start first clinical study in 2016
Paris (France), 31th May 2016 – Eyevensys, a privately held company developing a novel approach for the local delivery of therapeutic proteins to address unmet needs in ophthalmology, today announced it has appointed Dr. Patricia Zilliox, an experienced clinical development leader, to its Board of Directors. Eyevensys lead product EYS606, is due to enter a multi-centre European Phase I clinical study later in 2016. EYS606 is a combination of EyeCET, Eyevensys’ proprietary delivery system, with a soluble TNF receptor plasmid, which is being developed for non-infectious intermediate and posterior uveitis.
“We are delighted to welcome Patricia to the Board, said Francesco Sinigaglia, Chairman of Eyevensys. “Patricia has 25 years of global clinical development experience and I am confident that she will provide the Company with the insights and guidance we need to finalise our clinical development strategy as we plan the first clinical study with our unique delivery system, EyeCET. We believe EyeCET can be used to significantly improve the treatment of a broad range of ophthalmic indications.”
Dr. Zilliox, is currently the Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, in Columbia, MD, USA. From late 2008 until May 2011, Dr. Zilliox was head of clinical development at Alcon Laboratories, where she had global accountability for planning, development, execution, and management of pharmaceutical clinical programs in areas of eye diseases such as glaucoma, allergy, dry eye, infectious disease of the eye, and diseases of the retina, in particular dry and wet age-related macular degeneration. Dr. Zilliox previously worked for Alcon in Europe, where she was responsible of the conducting and executing the company’s European ophthalmology clinical trials. In this position she was based in Paris, France.
Dr. Zilliox said, “I am excited to join the board of Eyevensys and hope that my 25 years of experience in drug development in the field of retinal diseases, will allow me to contribute to the development of EyeCET, a new innovative delivery technology that I believe has the potential to have a huge impact on the treatment of ophthalmic disease.”
Eyevensys has developed its proprietary EyeCET system which uses electro-transfection to deliver therapeutic proteins into the eye to treat ocular disease. EyeCET, which injects these therapeutic proteins into the ciliary muscle, for the first time allows patients with ocular diseases to get non-viral gene-therapy that is effective for several months avoiding the toxicity, pain and waning efficacy that result from the sub-retinal injections of current therapies. Eyevensys’ lead product, EYS606, a combination of EyeCET with a soluble TNF receptor plasmid has been granted Orphan Drug Designation for the treatment of refractory Non-infectious intermediate and posterior uveitis. A multi-centre European Phase I clinical study with EYS606 is expected to begin later this year.